Study on Enfortumab Vedotin for Treating Adenoid Cystic Carcinoma

Inclusion Criteria

• Diagnosed with adenoid cystic carcinoma, including cases that do not originate from salivary glands.
• Cancer must have returned or spread and cannot be treated with other curative therapies.
• At least 4 weeks since last systemic treatment or 2 weeks since last radiotherapy, with recovery from any treatment-related side effects.
• Must have measurable disease as defined by specific medical criteria.
• Evidence of new or worsening disease within 6 months prior to joining the study.
• Aged 18 years or older.
• Good overall health with a performance status score of 0 or 1.
• Must provide a tissue sample from the primary tumor or metastases for study purposes.
• Meet specific blood and organ function criteria based on lab tests.
• Willing to sign an informed consent form.
• Men must agree to use contraception and not donate sperm during and for 4 months after treatment.
• Women must agree not to donate eggs during and for 3 weeks after treatment.
• Women of childbearing potential must use effective contraception during and for 2 months after treatment.

Exclusion Criteria

• Untreated brain metastases, unless stable and not requiring steroids.
• Recent history of another cancer, unless treated and disease-free for over 2 years.
• Recent systemic anti-cancer therapy within 4 weeks of starting the study.
• Significant nerve damage or eye conditions.
• Serious heart conditions or recent heart attack.
• Active infections requiring treatment.
• Positive for HIV, active Hepatitis B or C.
• History of lung disease requiring steroids.
• Kidney failure requiring dialysis.
• Breastfeeding during and for 3 weeks after treatment.
• Any condition that might interfere with the study or pose a risk to the participant.